Metrics as of 10/17/2026, 09:25 AM (Berlin time), refresh in progress.
Krystal Biotech Stock
Krystal Biotech, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Krish S. Krishnan
- Employees
- 295
- Market cap
- $9.4 B
- IPO
- 20/09/2017
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases. The company was established in 2015 and is headquartered in Pittsburgh, USA. Operating within the healthcare sector, Krystal Biotech is listed on the NASDAQ and employs 295…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Krystal Biotech stock: price history
1D
-4.1%
1W
-4.5%
1M
-6.0%
6M
+15.5%
YTD
+28.4%
1Y
+68.1%
2Y
+78.1%
5Y
+549.8%
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~33% stronger price swings than usual
Ask the agents about Krystal Biotech
Analyst assessment of Krystal Biotech
PRICE TARGET LOW
US$300.00
CONSENSUS
US$395.20
MEDIAN
US$400.00
PRICE TARGET HIGH
US$474.00
0
STRONG BUY
17
BUY
0
HOLD
0
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 15/10/2026
Krystal Biotech stock metrics
P/E
38.28
P/B
6.88
EV/EBITDA
40.69
RETURN ON EQUITY
4.0%
NET MARGIN
45.9%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.8%
FLOAT SHARES
23,618,391
AVG. DAILY VOLUME (30D)
285,190
Insider transactions (SEC)
Krishnan Suma
Krishnan Suma
Krishnan Suma
Krishnan Suma
Krishnan Krish S
Institutional holders
Comparable stocks
Frequently asked questions about Krystal Biotech stock
What does Krystal Biotech do?
Krystal Biotech, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Krish S. Krishnan, the company employs around 295 people.
The IPO was on 20/09/2017; the stock trades on NASDAQ under the ticker KRYS.
What do analysts say about Krystal Biotech stock?
17 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$395.20, ranging from US$300.00 to US$474.00, with a median of US$400.00.
This is an external assessment, not a statement by Market Jury.
When does Krystal Biotech report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
Does Krystal Biotech pay a dividend?
No, Krystal Biotech currently does not pay a dividend.
Which stocks are comparable to Krystal Biotech?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Krystal Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Krystal Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.